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Abstract 
Celiac disease is an autoimmune disorder primarily targeting the small bowel, although 
extraintestinal extensions have been reported. The autoimmune processes can affect 
the liver with manifestations such as primary biliary cirrhosis and autoimmune hepatitis. 
We describe a 61-year-old woman with celiac disease and an increased levels of 
aminotransferases. The persistence of increased levels of aminotransferases after 1 year 
of gluten-free diet and the positivity for an anti-nuclear and anti-double-strand DNA 
antibodies led to a misdiagnosis of systemic lupus erythematosus-related hepatitis. 
Based on these findings the patient was placed on steroids, which after a few months 
were stopped because of the onset of diabetes mellitus. Soon after steroid withdrawal, 
the patient had a marked increase in aminotransferases and γ-globulins, and a liver 
biopsy revealed chronic active hepatitis. A course of three months of steroids and 
azathioprine normalized both biochemical and clinical parameters. Currently the patient 
is symptom-free and doing well. In conclusion, a hypertransaminasemia persisting after a 
gluten-free diet should be interpreted as a sign of coexisting autoimmune liver disease. 
Any autoantibody positivity (in this case to ANA and anti-dsDNA) should be carefully 
considered in order to avoid misdiagnosis delaying appropriate clinical management.  
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Introduction 
Celiac disease (CD) is an autoimmune disorder triggered by the ingestion of wheat 
gliadins and/or other cereal prolamins in patients with genetic predisposition [1]. 
Although the small bowel is the main target of the disease with a resultant variable degree 
of malabsorption, growing evidence shows that CD is a systemic disorder that may affect 
several other organs outside the gut, i.e. the nervous system, thyroid, pancreas, connective 
tissue, bone, heart, skin, and liver [2]. The occurrence of liver impairment in CD is well 
established and can be regarded as one of the manifold extraintestinal presentations of 
gluten-sensitive enteropathy [3]. In this context, different patterns of liver injury can be 
observed in CD patients, including a close association with autoimmune liver disorders 
such as primary biliary cirrhosis, autoimmnune hepatitis and primary sclerosing 
cholangitis [4, 5]. Here we report the case of a CD patient with autoimmune hepatitis 
(AIH) whose liver involvement was initially attributed to systemic lupus erythematosus 
(SLE). This misdiagnosis delayed the definition of celiac-related AIH and appropriate 
management. 
Case Report 
A 61-year-old woman was evaluated for an unclear elevation of liver aminotransferases (both AST 
and ALT about 3 times above the normal limit) associated with a hyper-γ-globulinemia unrelated to 
hepatotropic viruses and toxic causes. Her past medical history was mainly characterized by two 
spontaneous miscarriages, iron deficiency anemia, osteopenia and alternating bowel habit. Due to the 
persistence of gastrointestinal symptoms, she underwent serological tests for CD that resulted positive 
for anti-endomysial antibodies (IgA EmA, 1:160). Duodenal biopsy revealed severe villous atrophy 
(3c according to the Marsh-Oberhüber classification). HLA typing revealed DQ2 (DQA1*0501, 
DQB1*0201) and DQ8 (DQB1*0302) heterodimer positivity. A diagnosis of CD was established and the 
patient was placed on a gluten-free diet (GFD) with remission of symptoms within about six months. 
After one year, routine serological tests still revealed an increase in AST and ALT aminotransferases 
(about 3 times above the normal limit). Other findings included a slight increase in bilirubin (1.5 mg/dl) 
and low levels of platelets (95,000/mm
3). Autoantibody profile was characterized by positive 
anti-nuclear antibody (ANA +++, homogenous pattern) and anti-double-strand DNA (anti-dsDNA 
1:160). A diagnosis of SLE with lupus-related hepatitis was made and steroidal therapy was started 
(prednisone 25 mg/day). Owing to the onset of steroid-induced diabetes mellitus, prednisone treatment 
was stopped. Soon after steroid withdrawal, the patient was referred to our unit. Laboratory tests 
showed a marked increase in AST and ALT aminotransferases (35 times above the normal limit), 
hyperbilirubinemia 4.05 mg/dl and high levels of total proteins (9.1 g/dl), albumin (3.8 g/dl), γ-globulins 
(3.6 g/dl), IgG (2,680 mg/dl), IgA (489 mg/dl) and IgM (273 mg/dl). The autoimmune profile confirmed 
a strong positivity of ANA (+++, with homogenous pattern), anti-smooth muscle antibodies (SMA, ++ 
with vessel pattern), anti-dsDNA (1:320), while CD-related autoantibodies were negative, showing a 
good compliance to GFD. Ultrasound-Doppler examination revealed an enlarged liver with irregular 
borders and coarse echo pattern along with signs of portal hypertension. A liver biopsy showed chronic 
active hepatitis with piecemeal necrosis and lympho-plasmacellular periportal infiltrate (fig. 1). A 
diagnosis of AIH associated with CD was made and the patient was treated with methylprednisolone 
(16 mg/day) and azathioprine (2 mg/kg = 100 mg/day). At 18-month follow-up, the patient was doing 
well with an almost complete normalization of aminotransferases (fig. 2), γ-globulins (fig. 3) and 
bilirubin. Methylprednisolone and azathioprine have been tapered down to the current dose of 
4 mg/day and 50 mg/day, respectively. The patient gave her informed consent to the publication of this 
case report.  
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Discussion 
The spectrum of liver abnormalities in the context of CD is particularly wide, however, 
two main forms of liver damage, i.e. cryptogenic and autoimmune, appear to be strictly 
associated with gluten-sensitive enteropathy [3]. Hypertransaminasemia has been 
reported in up to 47% of adults with a classical presentation of CD at the time of diagnosis 
[6]. Conversely, CD is present in about 9% of patients with chronic unexplained 
hypertransaminasemia and liver blood test abnormalities may also be the sole 
presentation of atypical CD [7]. In patients with untreated CD, cryptogenic liver disorder, 
also referred to as ‘celiac hepatitis’, is usually characterized by a mild increase in 
aminotransferase levels with normal values of bilirubin and γ-GT [8, 9]. A GFD leads to 
normalization of serum aminotransferases in almost all patients with CD within one year 
of good adherence to the diet [10]. In patients with missed or late diagnosis, CD may be 
also associated with severe forms of liver disease, including advanced cirrhosis which can 
require liver transplantation [11]. Sometimes the identification of CD in these patients 
can significantly improve liver function, leading to disappearance of ascites and jaundice, 
thereby avoiding liver transplantation [12]. 
Another clinically relevant association, which pertains to the present case report, is 
that between CD and autoimmune liver disorders. In this context, primary biliary 
cirrhosis is the most frequent liver disease found in patients with CD [13, 14]. In this case 
report, we describe the association between CD and type 1 AIH. Such an association has 
been demonstrated by two antibody screening studies for CD in large series of patients 
with AIH [4, 5]. One of these studies included the largest series of patients with AIH 
screened for CD with serology [4]. Based on serological response, the CD prevalence was 
4.4% (8.3% in type 2 AIH, 3.8% in type 1 AIH), whereas, taking into account only cases 
who underwent duodenal biopsy, CD prevalence was 2.8%. 
In the patient described here, GFD improved the symptoms attributable to CD due to 
normalization of the small intestinal mucosa, but it did not normalize aminotransferases. 
This finding along with the positivity for ANA (homogeneous pattern) and anti-dsDNA 
antibodies led to a misdiagnosis of SLE-related hepatitis. Based on the lack of clinical 
signs and symptoms suggesting SLE, the presence of these two autoantibodies should 
have been considered a clue to type 1 AIH [15] whose diagnosis could be supported by 
the detection of high-titer circulating SMA (vessel pattern). In addition, another relevant 
clinical feature of our patient suggesting type 1 AIH was the rebound of aminotransferase 
levels after steroid withdrawal. Finally, the histological pattern was consistent with AIH, 
showing chronic active hepatitis with piecemeal necrosis. 
The present case was a diagnostic challenge as it dealt with the interesting and not 
uncommon association between CD and liver disease. Accordingly, we propose the 
following conclusions: (a) Hypertransaminasemia can be secondary to CD-related 
hepatitis; it can as well be a clue for underlying coexisting autoimmune liver disease. For 
these reasons liver enzyme levels should be checked routinely in all patients with CD at 
diagnosis. (b) Once it has been established that hypertransaminasemia is of CD origin, 
liver enzymes should be controlled after 6–12 months after the beginning of a GFD. 
Persistently elevated levels of aminotransferases (once a poor compliance to the diet has 
been excluded) should be regarded as a sign of coexisting autoimmune liver disease other 
than celiac hepatitis, thus the etiology of liver disorder must be re-assessed. (c) The 
positivity of ANA and anti-dsDNA antibodies should not be regarded as uniquely  
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diagnostic for SLE, but these autoantibodies along with SMA suggest an underlying type 1 
AIH, particularly in the presence of very high levels of aminotransferases and γ-globulin. 
This case helps to shed light on the appropriateness and accurate interpretation of 
laboratory and diagnostic tests to establish a diagnosis of CD-related liver disease. 
Disclosure Statement 
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Fig. 1. Representative picture of liver biopsy of the reported case taken upon withdrawal of steroid 
treatment in association with a flare-up of aminotransferases and γ-globulins. Note the chronic active 
hepatitis characterized by piecemeal necrosis and lympho-plasmacellular infiltrate. H&E staining, 
original magnification 40x. 
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Fig. 2. Diagram showing ALT aminotransferases levels over time. At CD diagnosis and after 1 year of 
GFD the ALT levels remained steadily 3 times above the normal limit. In contrast, soon after steroid 
withdrawal a considerable flare-up of ALT levels was observed. This spike normalized after three 
months of a combined treatment of methylprednisolone and azathioprine. This normalization persisted 
after 18 months of immunosuppressive treatment which has been tapered down in the meantime. 
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Fig. 3. Diagram showing γ-globulin levels over time. Likewise aminotransferases, at CD diagnosis and 
after 1 year of GFD the γ-globulin levels remained slightly above the normal limit and increased 
markedly upon steroid withdrawal. Again, following a combined treatment of methylprednisolone and 
azathioprine, γ-globulin levels normalized within three months. These values remained stable after 
18 months of immunosuppressive treatment. 
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